Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126117311 | 12611731 | 1 | I | 20160720 | 20160801 | 20160801 | EXP | TR-ELI_LILLY_AND_COMPANY-TR201607012484 | ELI LILLY AND CO | 62.00 | YR | M | Y | 0.00000 | 20160801 | MD | TR | TR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126117311 | 12611731 | 1 | PS | OLANZAPINE. | OLANZAPINE | 1 | Oral | 2.5 MG, QD | Y | U | 20592 | 2.5 | MG | QD | |||||
| 126117311 | 12611731 | 2 | SS | OLANZAPINE. | OLANZAPINE | 1 | Unknown | 10 MG, QD | Y | U | 20592 | 10 | MG | QD | |||||
| 126117311 | 12611731 | 3 | SS | VENLAFAXINE | VENLAFAXINE HYDROCHLORIDE | 1 | Oral | 10 MG, QD | U | U | 0 | 10 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126117311 | 12611731 | 1 | Depression |
| 126117311 | 12611731 | 3 | Depression |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126117311 | 12611731 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126117311 | 12611731 | Hyponatraemia | |
| 126117311 | 12611731 | Insomnia | |
| 126117311 | 12611731 | Intentional product misuse | |
| 126117311 | 12611731 | Neuroleptic malignant syndrome |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |